Member Exclusive

Epigenetic modulator for cancer immunotherapy

4SC, an innovative German biotech company, is developing 4SC-202, a novel HDAC class I/LSD1 inhibitor for combination with cancer immunotherapy.

Go to the profile of Svetlana Hamm
Oct 10, 2016

Please sign in or register for FREE

Register to EpigenomicsNet – the epigenetics and epigenomics network

EpigenomicsNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.


No comments yet.